Zurich Cantonal Bank
BTAI icon

Zurich Cantonal Bank’s BioXcel Therapeutics BTAI Stock Holding History

Zurich Cantonal Bank’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Hold
2
– – ﹤0.01% 2542
2025
Q4 		$3 Sell
2
-101
-98% -$208 ﹤0.01% 2535
2025
Q3 		$264 Hold
103
– – ﹤0.01% 2537
2025
Q2 		$186 Hold
103
– – ﹤0.01% 2551
2025
Q1 		$209 Hold
103
– – ﹤0.01% 2620
2024
Q4 		$618 Sell
103
-274
-73% -$2.29K ﹤0.01% 2628
2024
Q3 		$3.68K Sell
377
-34
-8% -$457 ﹤0.01% 2633
2024
Q2 		$8.42K Sell
411
-67
-14% -$2.24K ﹤0.01% 2622
2024
Q1 		$21.6K Sell
478
-15
-3% -$716 ﹤0.01% 2622
2023
Q4 		$23.3K Sell
493
-220
-31% -$12.2K ﹤0.01% 2649
2023
Q3 		$28.9K Sell
713
-54
-7% -$5.46K ﹤0.01% 2681
2023
Q2 		$81.7K Buy
767
+11
+1% +$3.66K ﹤0.01% 2432
2023
Q1 		$226K Buy
756
+57
+8% +$24.3K ﹤0.01% 1793
2022
Q4 		$240K Buy
699
+233
+50% +$56.3K ﹤0.01% 1721
2022
Q3 		$88K Sell
466
-25
-5% -$5.8K ﹤0.01% 2321
2022
Q2 		$104K Sell
491
-22
-4% -$4.63K ﹤0.01% 2206
2022
Q1 		$172K Sell
513
-14
-3% -$4.06K ﹤0.01% 1982
2021
Q4 		$171K Buy
527
+3
+0.6% +$1.29K ﹤0.01% 2177
2021
Q3 		$254K Buy
524
+194
+59% +$85.3K ﹤0.01% 1760
2021
Q2 		$153K Buy
330
+12
+4% +$6.54K ﹤0.01% 1991
2021
Q1 		$219K Buy
318
+203
+177% +$163K ﹤0.01% 1724
2020
Q4 		$85K Hold
115
– – ﹤0.01% 2274
2020
Q3 		$80K Buy
+115
New +$86.3K ﹤0.01% 2077

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Zurich Cantonal Bank's BTAI Position: Q1 2026 in Review

Zurich Cantonal Bank held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 2 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

Zurich Cantonal Bank first reported a position in BTAI in Q3 2020 and has held it in 23 quarters since. The position peaked at $254K in Q3 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Zurich Cantonal Bank held 2 shares of BioXcel Therapeutics worth $3 as of Q1 2026.
  • Zurich Cantonal Bank left its BioXcel Therapeutics share count unchanged in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #2542 holding.
  • Zurich Cantonal Bank first reported a position in BioXcel Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Zurich Cantonal Bank's BioXcel Therapeutics position peaked at $254K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.